Stay updated on the latest breakthroughs in biotechnology. From advancements in gene editing technologies like CRISPR to developments in cell and gene therapies, explore how biotech is driving medical innovation and transforming patient care.
Richard Pazdur’s CDER appointment signals regulatory evolution; China’s biotech resurgence opens cross-border opportunities; medtech financing hits $26.6B as capital markets normalize The life sciences sector
Trump administration brokers obesity drug pricing pact with Novo and Lilly; FDA approves daratumumab for earlier-line myeloma; geopolitical tensions ease for Illumina while BD navigates
Market signals diverge as Charles River raises guidance while Bio-Techne misses; Eli Lilly’s expected weight-loss drug price cuts and medtech resilience add complexity to sector
An In-Depth Analysis of the Most Promising Biotech Innovators Reshaping Healthcare The biotechnology landscape is experiencing a renaissance. As we approach 2026, a new generation
November 5, 2025 Tuesday delivered a stark reminder of biotech’s unforgiving nature as Sarepta Therapeutics collapsed 40% following a devastating Duchenne muscular dystrophy confirmatory trial
Healthcare markets exploded with deal-making activity as November opened with a bang. Novartis dropped $12 billion to acquire Avidity Biosciences, Novo Nordisk and Pfizer escalated
Biotech delivered a sobering Halloween eve session as regulatory concerns collided with policy reforms and M&A speculation. Intellia Therapeutics’ CRISPR programs hit an FDA clinical
The healthcare sector delivered a remarkable week of innovation, deal-making, and regulatory transformation. From the FDA’s groundbreaking National Priority Review program to over $6.4 billion
Markets experienced significant turbulence this week as banking sector concerns collided with healthcare earnings, policy developments, and robust deal-making activity. Here’s everything you need to
Explore the latest biotech innovations from October 6-13, 2025: AstraZeneca’s oncology trials, FDA approvals for IPF and CSCC, allogeneic CAR-NK cells, and trends in direct-to-consumer
